Note 7. Stock-Based Compensation | Note 7: Stock-Based Compensation From time to time, the Company grants stock options and restricted stock unit awards to officers and employees of the Company. Additionally, the Company grants stock options and awards to directors as compensation for their service to the Company. In November 2010, the Company adopted the 2010 Stock Incentive Plan (the “2010 Plan”) which was restated in its entirety in August 2018. As amended, up to 2,600,000 shares of common stock were available for issuance under the Plan. The Plan provided for the issuance of stock options and other stock-based awards. As of March 31, 2021, no shares remain available for future issuance under the 2010 Plan. In April 2019, the Company adopted the 2019 Equity Incentive Plan (the “2019 Plan”), which was amend in July 2020. As amended no more than 1,025,000 shares of common stock, plus the number of shares of common stock underlying any award granted under the 2010 Plan that expires, terminates, is canceled, or is forfeited shall be available for grant under the 2019 Plan. The Plan provides for the issuance of stock options and other stock-based awards. During the terms of the Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Awards. Stock Options Stock option awards under the 2010 Plan and 2019 Plan (the “Plans”) have a 10-year maximum contractual term and, subject to the provisions regarding Ten Percent Shareholders, must be issued at an exercise price of not less than 100% of the fair market value of the common stock at the date of grant. The Plans are administered by the Board of Directors, which has the authority to determine to whom options may be granted, the period of exercise, and what other restrictions, if any, should apply. Vesting for awards granted to date under the Plans is principally over four years from the date of the grant, with 25% of the award vesting after one year and monthly vesting thereafter. Option awards are valued based on the grant date fair value of the instruments, net of estimated forfeitures, using a Black-Scholes option pricing model with the following assumptions: Three Months Ended March 31, 2021 2020 Volatility 52% 52% Risk Free Interest Rate 1.46% -1.66% 1.46%-1.66% Expected term 6.25 years 6.25 years The weighted average grant date fair value of stock options granted during the three months ended March 31, 2021, and 2020, was $9.59 and $5.68, respectively. For grants prior to January 1, 2015, the volatility assumption was based on historical volatility of similar sized companies due to lack of historical data of the Company’s stock price. For all grants subsequent to January 1, 2015, the volatility assumption reflects the Company’s historic stock volatility for the period of February 1, 2014 forward, which is the date the Company’s stock began actively trading. The risk-free interest rate was determined based on treasury securities with maturities equal to the expected term of the underlying award. The expected term was determined based on the simplified method outlined in Staff Accounting Bulletin No. 110. Stock option awards are expensed on a straight-line basis over the requisite service period. During the three months ended March 31, 2021, and 2020, the Company recognized stock compensation expense of $0.26 million and $0.22 million, respectively, associated with stock option awards. At March 31, 2021, future stock compensation expense associated with stock options (net of estimated forfeitures) not yet recognized was $2.76 million and will be recognized over a weighted average remaining vesting period of 2.85 years. The following summarizes stock option activity for the three months ended March 31, 2021: Weighted Average Weighted Remaining Aggregate Number of Average Contractual Intrinsic Options Exercise Price Life Value Outstanding at December 31, 2020 1,383,057 $ 7.60 7.1 $ 12,000,790 Granted 135,610 17.59 Exercised (22,056 ) 8.14 Expired (31 ) 11.98 Forfeited (76,547 ) 9.16 Outstanding at March 31, 2021 1,420,033 $ 8.46 7.0 $ 10,927,536 Exercisable at March 31, 2021 800,258 $ 6.24 5.7 $ 7,810,798 The total intrinsic value of stock options exercised during the three months ended March 31, 2021, and 2020, were $198,914 and $1,468, respectively. Restricted Stock Units Restricted Stock Units (“RSUs”) having a value equal to the fair market value of an identical number of shares of Common Stock, which may, but need not, provide that such restricted award may not be sold, assigned, transferred or otherwise disposed of, pledged or hypothecated as collateral for a loan or as security for the performance of any obligation or for any other purpose for a period determined by the Board of Directors. The Plans are administered by the Board of Directors, which has the authority to determine to whom RSUs may be granted, the period of exercise, and what other restrictions, if any, should apply. Vesting for awards granted to date under the Plans is generally over three years from the date of the grant, Need to the vesting term of "three' years at "33%" after "one" year and "quarterly" thereafter. During the three months ended March 31, 2021, and 2020, the Company granted 9,705 and 35,855 Restricted Stock Units (RSUs), respectively. RSUs are expensed using a graded vested schedule which are recorded on a straight-line basis over the requisite vesting period as if the award were, in substance, a single award. During the three months ended March 31, 2021, and 2020, the Company recognized stock compensation expense of approximately $0.08 million and $0.12 million, respectively, associated with RSUs. At March 31, 2021, future stock compensation expense associated with stock units (net of estimated forfeitures) not yet recognized was approximately $0.86 million and will be recognized over a weighted average remaining vesting period of 3.12 years. The following summarizes RSU activity for the period ended March 31, 2021: Weighted Average Grant Date Number of Fair Value Units Per Share Unvested at December 31, 2020 61,120 $ 15.06 Granted 9,705 26.50 Vested (4,454 ) 12.39 Unvested at March 31, 2021 66,371 $ 16.91 Restricted Stock Awards Restricted Stock Awards ("RSAs") are valued based on the closing price of our common stock on the date of grant, and compensation cost is recorded immediately if there is no vesting period. For awards granted that contain a graded vesting schedule, and the only condition for vesting is a service condition, compensation cost is recognized on a straight-line basis over the requisite vesting period as if the award were, in substance, a single award. During the three months ended March 31, 2021, and 2020, the company recognized stock compensation expense of approximately $0.05 million and $0.03 million, respectively, associated with our stock awards. As of March 31, 2021, future stock compensation expense associated with these awards (net of estimated forfeitures) not yet recognized was approximately $0.07 million and will be recognized over a weighted average remaining vesting period of 1 year. During the three months ended March 31, 2021, and 2020, the Company issued 1,784 and 2,680 shares, respectively, all of which were to non-employee directors as compensation for their service on the board. Such stock awards are immediately vested. The following table summarizes RSA activity for the period ended March 31, 2021: Average Grant Date Number of Fair Value Units Per Share Unvested at December 31, 2020 11,578 $ 9.57 Granted 1,784 20.68 Vested (1,784 ) 20.68 Unvested at March 31, 2021 11,578 $ 9.57 Additionally, during the quarter the Company entered into an agreement with Marietta Davis to issue 8,479 shares of common stock in recognition of Ms. Davis’s previous service to the Company as a member of the Board of Directors. Ms. Davis served as a member of the Board of Directors of the Company from 2017 until her resignation as of August 17, 2020. The Company recorded an expense of approximately $0.17 million associated with this issuance. These shares were not issued from the 2019 Equity Incentive Plan. |